[Evaluation of the protective effect of acellular DPT vaccine for booster immunization in 6-year-old children]
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A booster dose of the acellular DTP vaccine (DTaP) offers significant protection against pertussis in 6-year-old children, with effectiveness remaining strong up to 24 months post-vaccination.
Area Of Science
- Immunology
- Epidemiology
- Vaccinology
Background
- Pertussis (whooping cough) remains a public health concern, necessitating effective vaccination strategies.
- Booster doses are crucial for maintaining immunity against pertussis, especially as vaccine-induced protection wanes over time.
- Evaluating the epidemiological impact of DTaP booster doses in specific age groups is vital for optimizing immunization schedules.
Purpose Of The Study
- To assess the epidemiological protective effect of a DTaP booster dose against pertussis in 6-year-old children.
- To compare pertussis incidence rates between children receiving DTaP boosters and those receiving DT boosters.
Main Methods
- A retrospective cohort study design was employed.
- Participants included 960 six-year-old children, with 480 receiving DTaP boosters and 480 receiving DT boosters.
- Pertussis incidence was monitored over a two-year period following booster vaccination.
Main Results
- The DTaP group showed a pertussis incidence rate of 1.25% (6 cases), compared to 2.92% (14 cases) in the DT group.
- The overall vaccine effectiveness (VE) of DTaP against pertussis was 57.14%.
- VE remained substantial at 63.80% at 12 months and 64.59% at 18 months, with 57.60% at 24 months post-vaccination.
Conclusions
- Booster immunization with the DTaP vaccine provides measurable protection against pertussis in 6-year-old children.
- Significant protective efficacy was observed in the early period (0-6 months) and persisted effectively up to 24 months.
- The DTaP booster demonstrates sustained effectiveness, supporting its role in pertussis prevention in this age cohort.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
